Torrent Pharmaceuticals Ltd is one of the leading Indian Pharmaceutical Company engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations.
Q2 FY26 Earnings Results:
-
Revenue from Operations: ₹3,302 crore, up 14% YoY from ₹2,889 crore
-
EBITDA: ₹1,083 crore, up 15.3% YoY; EBITDA margin expanded to 32.8% (from 32.5% in Q2 FY25)
-
Net Profit (PAT): ₹591 crore, up 30.5% YoY from ₹453 crore
-
EPS: ₹17.46, up 30% YoY
-
PAT margin improved to 17.9% (from 15.7% in Q2 FY25)
-
India business revenue: ₹1,820 crore, up 12% YoY; chronic therapies (Cardiac +14%, Gastro +15%, Derma +29%) outpaced Indian Pharma Market (IPM) growth
-
Brazil revenue: ₹318 crore, up 21% YoY; US revenue: ₹337 crore, up 26% YoY (driven by new launches and volume gains); Germany business down 5% YoY (currency-adjusted) due to supply disruptions
-
Branded markets contributed 73% of sales
-
Strong operating cash flow and balance sheet
-
Company received regulatory approvals for JB Chemicals acquisition (expected closure: Jan 2026)
Management Commentary & Strategic Insights
-
Management highlighted outperformance in chronic and specialty portfolios in India, with new launches and PCPM gains
-
Branded markets (India, Brazil) and the US segment were called out as key value drivers, backed by market share gains and a mix of price, volume, and new launches
-
Germany expected to recover from supply headwinds by Q4 FY26
-
Focus remains on organic and inorganic growth; the JB Chemicals acquisition expected to expand branded portfolio and synergies
-
Ongoing investment in field force (adding 600 MRs in FY26E) and entry into new therapeutic areas forecast strong medium-term growth
-
Company reiterates guidance for sustained growth in India, US, Brazil, and margin-leveraging on volume and synergy realization post-acquisition
Q1 FY26 Earnings Results
-
Revenue from Operations: ₹3,177 crore, up 11.5% YoY
-
PAT: ₹548 crore, up 24% YoY
-
EBITDA: ₹1,033 crore, 32.5% margin
-
India business grew 12% YoY; US and Brazil growth continued
-
Margins remained healthy, with disciplined cost and product mix management
To view the company’s previous earnings and latest concall transcripts, click here to visit the Alphastreet India news channel.